Advanced ovarian carcinoma: A prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF)

✍ Scribed by J. Carmo-Pereira; F. Oliveira Costa; Elvira Henriques; J. Almeida Ricardo

• Publisher: John Wiley and Sons
• Year: 1981
• Tongue: English
• Weight: 367 KB
• Volume: 48
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19811101)48:9<1947::aid-cncr2820480906>3.0.co;2-m

✦ Synopsis

Fifty-seven evaluable patients with advanced ovarian carcinoma were randomized to receive either a combination of hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil (Hexa-CAF) or high-dose cyclophosphamide alone given intravenously intermittently. Objective responses were seen in 62% of patients receiving cyclophosphamide alone, and 36% of patients in the Hexa-CAF regimen, this difference being statistically significant (P < 0.05). The median duration of objective response (10 months vs. 9 months) and the median survival (1 1 months vs. 10 months) were greater in the cyclophosphamide group, but these differences were not statistically significant. It is concluded that there is no therapeutic advantage for the Hexa-CAF protocol over the alkyiating agent used alone.